CV-6209

Cat. No.: HY-109897

CAS No.: 100488-87-7

Molecular Formula: $C_{34}H_{60}ClN_3O_6$

Molecular Weight: 642.31

Target: Platelet-activating Factor Receptor (PAFR)

Pathway: GPCR/G Protein

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (155.69 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.5569 mL	7.7844 mL	15.5688 mL
	5 mM	0.3114 mL	1.5569 mL	3.1138 mL
	10 mM	0.1557 mL	0.7784 mL	1.5569 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

CV-6209 is a potent antagonist of platelet activating factor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC_{50}s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats[1].

IC_{50} & Target

platelet activating factor (PAF)[1]

In Vitro

CV-6209 inhibits [^{3}H]serotonin release from rabbit platelets stimulated with PAF (30 nM)[1].
CV-6209 has little action on platelet aggregation induced by arachidonic acid, ADP, or collagen[1].
CV-6209 (0.2-2 μM; pretreated for 30 min) inhibits PAF-induced MC degranulation in both LAD2 and hLMCs[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CV-6209 (i.v.) inhibits PAF (0.3 μg/kg; i.v.)-induced hypotension in rats (ED_{50}=0.009 mg/kg) with no effect on the hypotension induced by arachidonic acid, histamine, bradykinin and isoproterenol[1].
CV-6209 (66 μg; i.v.) reduces asparaginase-induced hypersensitivity compared with nonpretreated, sensitized mice[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Terashita Z, et, al. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242(1):263-8.

[2]. Munoz-Cano R, et, al. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). J Investig Allergol Clin Immunol. 2017;27(3):161-168.

[3]. Fernande CA, et, al. Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther. 2015 Mar;352(3):541-51.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA